Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes

American Journal of Surgical Pathology

Volumn 38, Issue 2, 2014, Pages 257-264

  Bishop, Justin A ^a,b   Montgomery, Elizabeth A ^a   Westra, William H ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

carcinosarcoma; head and neck squamous cell carcinoma; human papillomavirus; sarcomatoid carcinoma; spindle cell carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; ISOPROTEIN; KERATIN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; VIRUS DNA;

ARTICLE; CELL PROLIFERATION; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; GENETICS; HEAD AND NECK TUMOR; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; METHODOLOGY; OROPHARYNX TUMOR; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PREDICTIVE VALUE; SQUAMOUS CELL CARCINOMA; STROMA CELL; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KERATINS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROTEIN ISOFORMS; STROMAL CELLS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84893024884     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000119     Document Type: Article

References (45)

1. Nappi O, Wick MR. Sarcomatoid neoplasms of the respiratory tract. Semin Diagn Pathol. 1993;10:137-147.
2. Batsakis JG, Suarez P. Sarcomatoid carcinomas of the upper aerodigestive tracts. Adv Anat Pathol. 2000;7:282-293.
3. Cardesa A, Zidar N. Spindle cell carcinoma. In: Barnes L, Eveson JW, Reichart P, et al, eds. World Health Organization Classification of Tumours Pathology and Genetics of Head and Neck Tumors. Lyon, France: IARC Press; 2005:127-128.
4. Ansari-Lari MA, Hoque MO, Califano J, et al. Immunohistochem-ical p53 expression patterns in sarcomatoid carcinomas of the upper respiratory tract. Am J Surg Pathol. 2002;26:1024-1031.
5. Lane N. Pseudosarcoma (polypoid sarcoma-like masses) associated with squamous-cell carcinoma of the mouth, fauces, and larynx. Cancer. 1957;10:19-41.
6. Thompson LD, Wieneke JA, Miettinen M, et al. Spindle cell (sarcomatoid) carcinomas of the larynx: a clinicopathologic study of 187 cases. Am J Surg Pathol. 2002;26:153-170.
7. Zarbo RJ, Crissman JD, Venkat H, et al. Spindle-cell carcinoma of the upper aerodigestive tract mucosa. An immunohistologic and ultrastructural study of 18 biphasic tumors and comparison with seven monophasic spindle-cell tumors. Am J Surg Pathol. 1986;10:741-753.
8. Lewis JE, Olsen KD, Sebo TJ. Spindle cell carcinoma of the larynx: review of 26 cases including DNA content and immunohistochem-istry. Hum Pathol. 1997;28:664-673.
9. Lewis JS, Ritter JH, El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. Mod Pathol. 2005;18:1471-1481.
10. Brown DC, Theaker JM, Banks PM, et al. Cytokeratin expression in smooth muscle and smooth muscle tumours. Histopathology. 1987;11:477-486.
11. Gray MH, Rosenberg AE, Dickersin GR, et al. Cytokeratin expression in epithelioid vascular neoplasms. Hum Pathol. 1990;21:212-217.
12. Fletcher CD, Beham A, Bekir S, et al. Epithelioid angiosarcoma of deep soft tissue: a distinctive tumor readily mistaken for an epithelial neoplasm. Am J Surg Pathol. 1991;15:915-924.
13. Corson JM, Weiss LM, Banks-Schlegel SP, et al. Keratin proteins and carcinoembryonic antigen in synovial sarcomas: an immuno-histochemical study of 24 cases. Hum Pathol. 1984;15:615-621.
14. Muro-Cacho CA. The role of immunohistochemistry in the differential diagnosis of soft-tissue tumors. Cancer Control. 1998;5: 53-63.
15. Gu M, Antonescu CR, Guiter G, et al. Cytokeratin immunor-eactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol. 2000;24:410-416.
16. Miettinen M, Rapola J. Immunohistochemical spectrum of rhabdo-myosarcoma and rhabdomyosarcoma-like tumors. Expression of cytokeratin and the 68-kD neurofilament protein. Am J Surg Pathol. 1989;13:120-132.
17. Miettinen M. Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma. Arch Pathol Lab Med. 1988;112:637-640.
18. Coindre JM. Immunohistochemistry in the diagnosis of soft tissue tumours. Histopathology. 2003;43:1-16.
19. Hibshoosh H, Lattes R. Immunohistochemical and molecular genetic approaches to soft tissue tumor diagnosis: a primer. Semin Oncol. 1997;24:515-525.
20. Nakayama M, Wenig BM, Heffner DK. Atypical stromal cells in inflammatory nasal polyps: immunohistochemical and ultrastruc-tural analysis in defining histogenesis. Laryngoscope. 1995;105: 127-134.
21. Hall JM, Saenger JS, Fadare O. Diagnostic utility of P63 and CD10 in distinguishing cutaneous spindle cell/sarcomatoid squamous cell carcinomas and atypical fibroxanthomas. Int J Clin Exp Pathol. 2008;1:524-530.
22. Tse GM, Tan PH, Chaiwun B, et al. p63 is useful in the diagnosis of mammary metaplastic carcinomas. Pathology. 2006;38:16-20.
23. Reis-Filho JS, Schmitt FC. P63 expression in sarcomatoid/meta-plastic carcinomas of the breast. Histopathology. 2003;42:94-95.
24. Westfall DE, Folpe AL, Paner GP, et al. Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder. Am J Surg Pathol. 2009;33: 99-105.
25. Velazquez EF, Melamed J, Barreto JE, et al. Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases. Am J Surg Pathol. 2005;29:1152-1158.
26. Jo VY, Fletcher CD. p63 immunohistochemical staining is limited in soft tissue tumors. Am J Clin Pathol. 2011;136:762-766.
27. Kallen ME, Nunes Rosado FG, Gonzalez AL, et al. Occasional staining for p63 in malignant vascular tumors: a potential diagnostic pitfall. Pathol Oncol Res. 2011;18:97-100.
28. Crum CP, McKeon FD. P63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol. 2010;5:349-371.
29. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25:405-415.
30. Lin Z, Liu M, Li Z, et al. DeltaNp63 protein expression in uterine cervical and endometrial cancers. J Cancer Res Clin Oncol. 2006;132:811-816.
31. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA. 2000; 97:5462-5467.
32. Pelosi G, Sonzogni A, Papotti M, et al. Different prevalence of transactivating (TA) p63 and non-TAp63 isoforms in pulmonary adenocarcinomas: a useful diagnostic tool. Mod Pathol. 2010;23:411A-412A.
33. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011;117:3416-3423.
34. Del Vescovo V, Cantaloni C, Cucino A, et al. miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol. 2011;35:268-275.
35. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
36. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709-720.
37. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus. summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009;31:1393-1422.
38. Lewis JS Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012;6(suppl 1):S75-S82.
39. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010;116:2166-2173.
40. Ruzevick J, Olivi A, Westra WH. Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer. J Neurooncol. 2013;112:449-454.
41. Bishop JA, Ogawa T, Chang X, et al. HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol. 2012;36:142-148.
42. Bishop JA, Westra WH. Human papillomavirus-related small cell carcinoma of the oropharynx. Am J Surg Pathol. 2011;35: 1679-1684.
43. Kraft S, Faquin WC, Krane JF. HPV-associated neuroendocrine carcinoma of the oropharynx: a rare new entity with potentially aggressive clinical behavior. Am J Surg Pathol. 2012;36:321-330.
44. Watson RF, Chernock RD, Wang X, et al. Spindle cell carcinomas of the head and neck rarely harbor transcriptionally-active human papillomavirus. Head Neck Pathol. 2013;7:250-257.
45. Ernster JA, Sciotto CG, O'Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope. 2007;117:2115-2128.